Ausbil Investment Management Ltd Buys 664 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Ausbil Investment Management Ltd increased its holdings in Medpace Holdings, Inc. by 33.7% during the second quarter, acquiring an additional 664 shares, bringing its total to 2,636 shares valued at $827,000.
• Medpace reported a quarterly EPS of $3.10, exceeding analysts' expectations of $3.00, alongside a revenue of $603.31 million, marking a 14.2% year-over-year growth.
• Insider selling activity saw Medpace’s president sell 41,801 shares for approximately $18.94 million, reducing his ownership by 53.38%, amidst a broader trend of insider sales totaling over $74 million in recent months.

Ausbil Investment Management Ltd lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 33.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,636 shares of the company's stock after purchasing an additional 664 shares during the quarter. Ausbil Investment Management Ltd's holdings in Medpace were worth $827,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Wealth Enhancement Advisory Services LLC increased its holdings in Medpace by 245.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,371 shares of the company's stock worth $2,781,000 after buying an additional 5,949 shares during the last quarter. GAMMA Investing LLC increased its holdings in Medpace by 41,658.9% during the first quarter. GAMMA Investing LLC now owns 93,540 shares of the company's stock worth $28,501,000 after buying an additional 93,316 shares during the last quarter. NBC Securities Inc. acquired a new position in Medpace during the first quarter worth $593,000. Merit Financial Group LLC increased its holdings in Medpace by 25.3% during the first quarter. Merit Financial Group LLC now owns 2,289 shares of the company's stock worth $697,000 after buying an additional 462 shares during the last quarter. Finally, HBW Advisory Services LLC increased its holdings in Medpace by 10.7% during the first quarter. HBW Advisory Services LLC now owns 837 shares of the company's stock worth $255,000 after buying an additional 81 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

NASDAQ:MEDP opened at $496.79 on Friday. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $506.55. The company has a market cap of $13.96 billion, a P/E ratio of 36.94, a P/E/G ratio of 3.13 and a beta of 1.44. The firm's fifty day moving average price is $464.83 and its two-hundred day moving average price is $361.00.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same period in the prior year, the company posted $2.75 earnings per share. Medpace's revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 41,801 shares of the company's stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $453.11, for a total value of $18,940,451.11. Following the transaction, the president directly owned 36,503 shares in the company, valued at approximately $16,539,874.33. This represents a 53.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Susan E. Burwig sold 10,000 shares of the company's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the transaction, the vice president owned 57,500 shares in the company, valued at $27,600,000. This trade represents a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 161,266 shares of company stock valued at $74,111,427 in the last three months. Insiders own 20.30% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group boosted their target price on shares of Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a report on Tuesday, September 9th. Rothschild Redb downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 3rd. William Blair restated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and boosted their target price for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Finally, Robert W. Baird upped their price objective on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Medpace currently has a consensus rating of "Reduce" and a consensus price target of $422.27.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.